Skip to main content

RheumNow Podcast – Falling or Falling in Love?

May 06, 2021 9:38 pm

Dr. Jack Cush reviews the best journal articles from the past week on

  1. Study of healthcare resource utilization and costs psoriasis, psoriatic arthritis (PsA) vs controls; PsA has the highest annual all-cause healthcare costs per patient - Controls =$7,470, Psoriasis= $11,062, and PsA = $29,742
  2. Falls are not uncommon in #RA patients; significant risk factors for falls include being elderly, un-married, higher pain scores, reported dizziness taking psychotropic medications and having lower HRQoL scores
  3. Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis
  4. TNF inhibitor induced (paradoxical) psoriasis in JIA patients was 3 fold higher when TNFi was used - data from 8,222 children in the CARRA registry (54% used TNFi) - rate 8.5 cases/1000PY.
  5. Nested case–control study from the Danish (DANBIO) Register and 8019 Psoriatic arthritis patients shows that pain alone does not influence mortality risk; however steroid and comorbidities do!
  6. Risk factors for Kawasaki disease in Taiwan compared 4197 KD pts to controls. KD was more common in Males (OR 1.47), older mothers (>35 y; OR, 1.18), and in multivariable analysis, maternal ankylosing spondylitis (OR 2.02).
  7. Real world comparision of baricitinib (n 138) and tofacitinib (n 156) in #RA patients shows at wk 24, BARI out performed TOFA - CDAI remission (40.4 vs 28.3%) and CDAI LDA (81.6 vs 69.3%); safety signals were equal between groups.
  8. Metanalysis of 9 studies, and 1132 lupus pregnancies shows that hydroxychloroquine treatment significantly reduced the risk of preeclampsia (OR 0.35), pregnancy hypertension (OR 0.41)and prematurity (OR 0.55), but no effect on rates of HELLP, DM, Ab rates
  9. Childhood Lupus May Hamper Adult Careers 
  10. Drug Monitoring Ineffective with Infliximab Treatment 
  11. Uric Acid: A Major Player in the Metabolic Syndrome
  12. BACK TALK 
  13. TNR – last weeks replay of RNL 2021 on Psoriatic disease 
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.